Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety

We evaluated the pharmacokinetics, pharmacodynamics, and safety of evolocumab, a fully human monoclonal antibody against proprotein convertase subtilisin kexin type 9 (PCSK9), in an open‐label, parallel‐design study in participants with normal renal function (n = 6), severe renal impairment (RI; n =...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical pharmacology in drug development 2019-04, Vol.8 (3), p.281-289
Hauptverfasser:	Lee, Edward, Gibbs, John P., Emery, Maurice G., Block, Geoffrey, Wasserman, Scott M., Hamilton, Lisa, Kasichayanula, Sreeneeranj, Hanafin, Patrick, Somaratne, Ransi, Egbuna, Ogo
Format:	Artikel
Sprache:	eng
Schlagworte:	evolocumab Hemodialysis human monoclonal antibody Kidney diseases LDL‐C Monoclonal antibodies Original Manuscript PCSK9 Pharmacodynamics pharmacokinetics and pharmacodynamics Pharmacology renal impairment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!